Announcements Trials
Browse Landscape

Status

Recruiting 2Completed 2Not yet recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Recurrence 1Neoplasm Metastasis 1

Interventions

Observation 21Blood Specimen Collection 20Drug Therapy 13Surveys and Questionnaires 8Surgical Procedures, Operative 8Immunotherapy 7Immune Checkpoint Inhibitors 7Positron Emission Tomography Computed Tomography 5Hematologic Tests 5Watchful Waiting 4Neoadjuvant Therapy 4Fluorodeoxyglucose F18 4Bevacizumab 4darolutamide 3Tyrosine Kinase Inhibitors 3Therapeutics 3Standard of Care 3Radiotherapy 3Indocyanine Green 3Imatinib Mesylate 3Endoscopic Mucosal Resection 3Docetaxel 3Cyclophosphamide 3Capecitabine 3Artificial Intelligence 3tislelizumab 2pertuzumab 2palbociclib 2obinutuzumab 2nilotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Observational × Combined Modality Therapy × Clear all
NCT06993506 2025-05-29

Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not yet recruiting
500 enrolled

Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡